MaxCyte CEO Maher Masoud discusses how new treatment methods are providing greater control of the therapy’s safety profile.
Maher Masoud
Advertisement
Maher Masoud is CEO of MaxCyte.
Articles by Maher Masoud
Maher Masoud, CEO of MaxCyte, discusses the need for developers to come together with platforms.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Top Drugs at Risk of Supply Shortages: Report
2
Amazon One Medical Launches GLP-1 Management Program
3
How Compounding Has Become a Permanent Bridge for Healthcare Access: Q&A with Dr. Nicole Snow
4
FDA Approves Idvynso for Treatment of HIV-1 Infection in Adults
5